8 - 17 - 01

```
<110>    KOHNO, TADAHIKO

<120>    APO-AI/AII PEPTIDE DERIVATIVES

<130>    A-690

<140>    09/840,669
<141>    2001-04-23

<150>    60/198,920
<151>    2000-04-21

<160>    11

<170>    PatentIn version 3.1

<210>    1
<211>    684
<212>    DNA
<213>    Homo sapiens

<220>
<221>    CDS
<222>    (1)..(684)
<223>


<400>    1
atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc ctg        48
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1               5                   10                  15

ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc        96
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
                20                  25                  30

atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc       144
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
            35                  40                  45

cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag       192
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
        50                  55                  60

gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg       240
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65                  70                  75                  80

tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat       288
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
                85                  90                  95

ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc       336
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
                100                 105                 110

atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag       384
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
            115                 120                 125

gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc       432
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
        130                 135                 140

agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg       480
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
```

```
145                     150                     155                     160
gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct     528
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
            165                     170                     175
ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc     576
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
            180                     185                     190
gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg     624
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
            195                     200                     205
atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg     672
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
    210                     215                     220
tct ccg ggt aaa                                                       684
Ser Pro Gly Lys
225
```

```
<210>   2
<211>   228
<212>   PRT
<213>   Homo sapiens

<400>   2

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1               5                   10                  15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
            20                  25                  30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
        35                  40                  45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
    50                  55                  60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65                  70                  75                  80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
                85                  90                  95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
            100                 105                 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
            115                 120                 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
    130                 135                 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145                 150                 155                 160
```

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
                165   170   175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
            180   185   190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
        195   200   205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
    210   215   220

Ser Pro Gly Lys
225

<210>   3
<211>   8
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Preferred linker

<400>   3

Gly Gly Gly Lys Gly Gly Gly Gly
1   5

<210>   4
<211>   7
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Preferred linker

<400>   4

Gly Gly Asn Gly Ser Gly Gly
1   5

<210>   5
<211>   8
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Preferred linker

<400>   5

Gly Gly Gly Cys Gly Gly Gly Gly
1   5

<210>   6
<211>   5
<212>   PRT
<213>   Artificial Sequence

```
<220>
<223>  Preferred linker

<400>  6

Gly Pro Asn Gly Gly
1               5


<210>  7
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  7

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1               5                   10                  15


Ala Phe



<210>  8
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Preferred embodiments

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Fc domain attached at Position 18 through an optional linker


<400>  8

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1               5                   10                  15


Ala Phe



<210>  9
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Preferred embodiments

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Fc domain attached through optional linker


<400>  9
```

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1   5   10   15

Ala Phe

<210> 10
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Preferred embodiments

<220>
<221> misc_feature
<222> (19)..(19)
<223> Attached by optional linker to identical sequence, which is attac
       hed by optional linker to an Fc domain

<400> 10

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1   5   10   15

Ala Phe

<210> 11
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Preferred embodiments

<220>
<221> misc_feature
<222> (1)..(1)
<223> Attached by optional linker to Fc domain at the N-terminus.

<220>
<221> misc_feature
<222> (18)..(18)
<223> Attached by optional linker to an identical sequence

<400> 11

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1   5   10   15

Ala Phe